Genmab A (GMAB) Non-Current Deffered Revenue (2023 - 2025)

Genmab A (GMAB) has reported Non-Current Deffered Revenue for 3 consecutive years, with $95.0 million the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Non-Current Deffered Revenue rose 112.72% year-over-year to $95.0 million; the trailing twelve-month figure through Dec 2025 stood at $95.0 million (up 112.72% YoY), and the FY2025 full-year result was $95.0 million, up 112.72% from the prior year.
• Non-Current Deffered Revenue rose to $95.0 million in Q4 2025 per GMAB's latest filing, from $44.7 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $95.0 million in Q4 2025 and bottomed at $44.7 million in Q4 2024.
• Historically, Non-Current Deffered Revenue has averaged $61.6 million across 3 years, with a median of $45.1 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Non-Current Deffered Revenue retreated 0.96% in 2024, then soared 112.72% in 2025.
• Over 3 years, Non-Current Deffered Revenue stood at $45.1 million in 2023, then retreated by 0.96% to $44.7 million in 2024, then jumped by 112.72% to $95.0 million in 2025.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $95.0 million, $44.7 million, and $45.1 million for Q4 2025, Q4 2024, and Q4 2023 respectively.